Defining a patient-centered approach to cancer survivorship care: development of the patient centered survivorship care index (PC-SCI)

K. Holly Mead¹, Yan Wang¹, Sean Cleary¹, Hannah Arem²,³ and Mandi L. Pratt-Chapman⁴*

Abstract

Purpose: This study presents the validation of an index that defines and measures a patient-centered approach to quality survivorship care.

Methods: We conducted a national survey of 1,278 survivors of breast, prostate, and colorectal cancers to identify their priorities for cancer survivorship care. We identified 42 items that were “very important or absolutely essential” to study participants. We then conducted exploratory and confirmatory factor analyses (EFA/CFA) to develop and validate the Patient-Centered Survivorship Care Index (PC-SCI).

Results: A seven-factor structure was identified based on EFA on a randomly split half sample and then validated by CFA based on the other half sample. The seven factors include: (1) information and support in survivorship (7 items), (2) having a medical home (10 items) (3) patient engagement in care (3 items), (4) care coordination (5 items), (5) insurance navigation (3 items), (6) care transitions from oncologist to primary care (3 items), and (7) prevention and wellness services (5 items). All factors have excellent composite reliabilities (Cronbach’s alpha 0.84-0.94, Coefficient of Omega: 0.81-0.94).

Conclusions: Providing quality post-treatment care is critical for the long-term health and well-being of survivors. The PC-SCI defines a patient-centered approach to survivorship care to complement clinical practice guidelines. The PC-SCI has acceptable composite reliability, providing the field with a valid instrument of patient-centered survivorship care. The PC-SCI provides cancer centers with a means to guide, measure and monitor the development of their survivorship care to align with patient priorities of care.

Trial registration: ClinicalTrials.gov ID: NCT02362750, 13 February 2015

Keywords: Patient-Centered, Survivorship Care, Index, Measures, Confirmatory Factor Analysis

Introduction

Americans diagnosed with cancer today have a nearly seven in 10 chance of surviving 5 years, leaving a substantial population with unique health care needs. In 2019, there were nearly 17 million cancer survivors (defined from the moment of diagnosis) and this number is projected to grow to 21.7 million by 2030 [1, 2]. Cancer
survivors\textsuperscript{1} suffer myriad physical and psycho-social consequences of cancer and its treatment, including pain, fatigue, anxiety, and depression, as well as practical concerns such as health insurance challenges and financial hardships. While some of these issues are short-lived, late-emerging and long-term effects, such as neurologic sequelae, fatigue, cardiomyopathy, fertility issues, and long-term emotional distress, affect many survivors for years \cite{3–6}.

The unique challenges of cancer survivorship have created the need for a distinct, post-treatment phase of cancer care that shifts the focus from treating the disease to managing the chronic effects of cancer and focusing on the quality of life of survivors over the long term \cite{3, 7, 8}. In response to this need, the National Policy Forum of the National Academies of Sciences, Engineering and Medicine (NASEM) issued a call to action in 2006 and the Commission on Cancer began requiring focused attention on the post-treatment care of cancer survivors \cite{9}. Subsequently, a variety of care models have arisen, including nurse-led models \cite{10, 11}, primary care models \cite{12}, models in which oncology and primary care share different aspects of post-treatment care \cite{13}, transitional care models \cite{14}, and—most recently—virtual care models \cite{15}. As survivorship care programs work to address the needs of this growing patient population, cancer researchers and providers are in need of guidelines and strategies to clearly define, measure and implement high quality, patient-centered survivorship care across all models of care \cite{6, 9}.

Cancer survivorship care should encompass all follow-up care, referrals and resources needed by survivors to manage their long-term health, including monitoring and surveillance for new and returning cancers, preventive and risk-management services, care for ongoing and late-emerging physical symptoms, management of co-morbidities, support for emotional issues, and help with financial and practical concerns \cite{3, 16}. Moreover, because of the heterogenous impact of cancer on patients' health and well-being, survivorship care should also offer a patient-centered approach that prioritizes patients' individual preferences and needs to optimize their understanding of and engagement in their care. Studies suggest that patient-centered care can enhance quality of care and improve clinical outcomes \cite{17–22}. When patients' priorities are met, they experience higher self-efficacy and better self-management of their care, greater adherence to health promotion strategies, decreased suffering and symptom burden, and improved quality of life \cite{17, 23}. Much of the effort to improve quality cancer care for survivors in the U.S. has focused on the implementation of important clinical metrics, however, patient-centered strategies that directly address the practices and interactions that ensure patients' priorities for care are being met may be overlooked.

Patient-centered care in cancer survivorship is a concept that has not been fully developed or translated into clinical practice. A number of studies have examined patients' preferences and found a need for greater awareness and information about life after cancer treatment, tools to engage patients in their care, improved communication between providers and patients, increased access to risk-management and health promotion services, and better care coordination, particularly around transitions in care \cite{23–28}. Some studies outside the U.S. have developed patient-centered measures for cancer care, setting precedent for the importance of integrating patient-centered care into clinical guidance. Few studies looking at the U.S. cancer care system, however, have examined how to holistically address patient-centered survivorship needs in practice, and, to our knowledge, there are no extant tools that measure and evaluate the multiple dimensions of patient-centeredness in survivorship care from patients' perspectives, although a recently published framework identifies important elements of care as defined by survivorship experts \cite{24, 29, 30}.

The purpose of this study is to develop and validate a survivorship care index to more clearly define and operationalize a patient-centered approach to survivorship care. The Patient-Centered Survivorship Care Index (PC-SCI) provides a systematic approach to identifying and implementing practices that advance survivors' priorities for post-treatment cancer care. Moreover, the PC-SCI offers cancer survivorship care providers a framework to organize high quality, patient-centered survivorship care and a tool to assess how well survivorship care meets patients' goals and values. We hypothesized that there were several different latent constructs underlying the cancer patients' survivorship care priorities. This study was registered on ClinicalTrials.gov, ID: NCT02362750, on 13 February 2015.

\textbf{Methods}

\textbf{Study approach}

We developed the PC-SCI as part of a larger comparative effectiveness research (CER) project, Evaluating Cancer

---

\textsuperscript{1} A person is considered a cancer survivor from the time of diagnosis until the time of death [1]. However, because we are looking at the system of care provided to survivors post-treatment, we use the American Society of Clinical Oncology’s “functional definition,” which considers survivors to be those “individuals who have successfully completed curative treatment of those who have transitioned to maintenance of prophylactic therapy” [5].
Survivorship Care Models, which examined the impact of different models of survivorship care on patient outcomes. The PC-SCI was the primary measure of patient-centered care in the CER study and was used to evaluate the patient-centered approach of 32 survivorship care programs across the United States and examine their effectiveness in addressing survivors’ sense of self-efficacy, health care utilization, and physical and emotional quality of life [31].

In the formative phase, we conducted a qualitative study comprising 22 focus groups with 170 breast, prostate and colorectal cancer survivors to identify patients’ priorities for survivorship care. The PC-SCI was developed based on the results of this work, which identified care practices that participants characterized as patient-centered priorities for survivorship care. Information on the methodology and results of the qualitative formative work have been reported elsewhere [24]. In this phase of the research, we conducted a national survey of breast, prostate and colorectal cancer patients to develop and validate the PC-SCI using exploratory and confirmatory factor analysis (EFA/CFA). The George Washington University Institutional Review Board approved the study (#101308).

Survey development

Following the qualitative analysis, we conducted a national survey of breast, prostate and colorectal cancer survivors to further examine their perspectives on patient-centered survivorship care and identify specific practice items that survivors consider to be most important in survivorship care. The objectives of the survey were to develop and validate a multiple-factor index that represents survivors’ priorities for care. The survey was developed around the practice priorities identified in the qualitative analysis and reflected survivors’ preferences for survivorship care. We limited the survey sample to survivors of the three most common cancers to facilitate sampling and ensure we had a large enough sample to conduct the analysis. We also were interested in examining common experiences among survivors of different types of cancers to better understand how survivorship care can be better organized to address all survivors’ needs, which we did in the formative work.

Most items in the survey were adapted from publicly available, validated instruments with related constructs around components of patient-centeredness and quality [32–40]. We did not find an instrument specific to survivors’ desire for a patient-centered medical home (PCMH) and, instead drew from the literature and guidance, an organizational PCMH assessment tool and guidance from a community advisory board (CAB) comprised of cancer survivor and cancer survivorship care provider stakeholders to develop new items for this concept. We conducted 15 cognitive interviews to test item readability and comprehension, appropriateness of response categories, correct frame of reference, and understanding of specific terminology. The final survey consisted of a total of 68 items representing specific services and practices that operationalize patient-centered care priorities from the formative work. Using a 5-point Likert scale, survey questions asked survivors to report on the patient-centeredness of care by rating “how important it is” to receive elements of care related to psychosocial support, information and resources, self-management, clinician support, clinician-patient communication, care coordination, holistic care, practical life support and having a medical home. The range of the 5-point Likert scale was as follows: 1=not important, 2=somewhat important, 3=important, 4=very important and 5=absolutely essential.

Sample design and survey administration

We contracted with GfK Knowledge Networks to field an internet-based survey from August-September of 2014. The study population was a blended sample consisting of GfK’s KnowledgePanel® (KP), a probability-based web panel, and a non-probability opt-in sample, to oversample participants who had been diagnosed with cancer and to achieve a proportionate distribution of breast, prostate and colorectal cancer survivors. Eligible respondents were non-institutionalized adults ages 18 and older in the U.S. who had been diagnosed with breast, prostate or colorectal cancer and had completed active treatment at any point in time. GfK used a calibrated weighting system to ensure the blended sample was representative of our target population. We targeted a sample size of 1,270 to ensure precision in our statistical estimates. The estimated sample size needed for the survey was based on estimates of the proportion of the sample endorsing each element of quality and the magnitude of the differences between the ranked elements. A small effect size ($f = .10$) was estimated to be a 10-15% difference. The target sample size for the web-based survey was 1,269 with alpha 3

3 The GfK calibration weighting allows the sample from the KP probability sample and the opt-in sample to be blended and better represent our study’s target population. It identifies how respondents from the two panels respond differently to specific questions and applies correcting weights to realign the opt-in panel respondents with the probability-based KP. This improved representation reflects basic geo-demographic distributions, as well as important attitudinal and behavioral measures. The methodology is widely used in published studies.
= 0.05 and 90% power. The survey was disseminated to 97,329 panelists in the blended panel, and data were collected until the desired sample was achieved. Given GfK’s sampling strategy of using a pre-enrolled probability-based panel for surveys, the firm reports completion rates rather than response rates; completion rates reflect the percent of panelists, who completed the preliminary screening survey and main survey. Table 1 presents the number of respondents in both the probability-based web panel and the non-probability opt-in sample. A total of 1,278 participants were eligible for and completed the survey.

To determine survivors’ most important priorities for survivorship care, survey participants were asked to reflect on the 68 survivorship care items in the survey and score each items’ importance. Items were classified as critical to patients’ survivorship care when: (1) the majority (≥50%) of respondents reported the item as either “3=important,” “4=very important,” or “5=absolutely essential” and (2) at least ≥30 percent indicated the item as “4=very important” or “5=absolutely essential.”

**Statistical analyses**

We conducted exploratory factor analyses (EFA) to identify factors and items for the PC-SCI and then confirmatory factor analysis (CFA) to validate the factor structure. The sample of survey respondents was randomly split into testing (n = 639) and validation (n = 639) groups. EFA was run first with no predetermined factor structure and no restrictions to explore the factor structure within half of the sample. The suitability of factor analysis was verified by calculating the Kaiser-Meyer-Olkin (KMO) index of sampling adequacy (> .80) [41] and Bartlett’s test of sphericity (with p < .05) [42]. The Robust Maximum Likelihood (RML) estimation method, with an oblique rotation (Geomin) [43], was used because we anticipated moderate correlations between factors and to account for possible non-normal distributions of the items. For the EFA, the number of factors was determined based on several criteria: (1) the Kaiser’s criteria of retaining all factors with eigenvalues≥1 [44, 45] (2) Cattell’s scree plot based on eigenvalues and retaining the factors before the break point in the line [46], (3) Hom’s parallel analysis that retains the number of factors at the crossing point of the screen plot and eigenvalues estimated from a set of random variables [47, 48] and (4) theoretical meaningfulness. Then confirmatory factor analysis (CFA) was conducted based on the results of EFA to validate the factor structure. For the model fit of the CFA, standard fit was examined to identify the final model statistics, including RMSEA, CFI, TLI, SRMR. X² test was sensitive to sample size and is biased with a large sample size. RMSEA<0.08, CFI>0.9 and SRMR<0.08 were deemed acceptable fit [49]. Missing items were treated with full information maximum likelihood (FIML) in the EFA and CFA models. The

**Table 1 National survivorship care survey participant characteristics**

| Characteristic | n = 1278 |
|---------------|----------|
| Age, M Mean | 64 |
| Gender, N (%) female | 719 (56.3) |
| Cancer site, N (%) Breast | 679 (53.1) |
| Prostate | 451 (35.3) |
| Colorectal | 148 (11.6) |
| Stage at diagnosis, N (%) Stage 0 | 157 (12.3) |
| Stage 1 | 385 (30.1) |
| Stage 2 | 227 (17.8) |
| Stage 3 | 227 (9.8) |
| Stage 4 | 36 (2.8) |
| Don’t Know | 345 (31) |
| Time since cancer diagnosis, N (%) <1 year | 38 (3.0) |
| 1-10 years | 800 (62.7) |
| 11-20 years | 341 (26.7) |
| 21-30 years | 79 (6.2) |
| 31-40 years | 16 (1.3) |
| 41-50 years | 2 (0.0) |
| Treatment, N (%) Surgery | 1033 (80.8) |
| Chemotherapy | 433 (33.9) |
| Radiation | 637 (49.8) |
| Hormonal therapy | 398 (31.1) |
| Other | 81 (6.3) |
| Race, N (%) White | 1099 (86) |
| Black | 63 (4.9) |
| Other | 50 (3.9) |
| Hispanic ethnicity, N (%) yes | 66 (6.2) |
| Insurance status N (%) yes | 1259 (98.5) |
| Insurance type Private | 642 (50.2) |
| Medicare | 783 (61.3) |
| Medicare supplement | 389 (30.4) |
| Medicaid | 85 (6.7) |
| Other | 54 (4.2) |

Note: Percentages are calculated based on valid counts and exclude missing data
internal consistency for each factor was assessed with Cronbach's alpha and coefficient omega, separately, with high values indicating high reliabilities [50]. All the analyses accounted for the sampling weight in the survey. The research team conducted EFA/CFA using Mplus 8.4 statistical software and KMO and Bartlett's tests were conducted with STATA 16 statistical software.

**Results**

**Sample characteristics**

The average age of survey participants was 64 years, and 56 percent were female (Table 1). Just over half (53 percent) had been diagnosed with breast cancer, 35 percent with prostate cancer, and 12 percent with colorectal cancer. The majority of participants self-reported as White (86 percent), five percent self-reported as African American, and six percent as Hispanic. Over half (63 percent) of the sample had been diagnosed within one to 10 years and 27 percent had been diagnosed with cancer within 11 to 20 years of the survey. Nearly 99 percent had some form of insurance.

**Content validity**

Forty-two survey items were determined to be patient-centered priorities for survivorship care based on the threshold of ≥30 percent of participants scoring them as "very important or absolutely essential" (see Table 2). The 42 items were reviewed by the CAB and the research team to assess content validity. The research team eliminated four items due to redundancy in content, leaving 38 items for the EFA (See Table 2). The absolute values for skewness of each item ranged within 2, and the absolute values for kurtosis ranged within 3.

**Construct validity**

The data showed good sampling adequacy (KMO>0.9) and Bartlett's test of sphericity was significant (x²=16973, df=703, p<0.001). In the 38-item EFA, we analyzed models with increasing factors from 1-factor to 12-factors using Geomin rotation with robust maximum likelihood. Different models were preferred based on our evaluation criteria; the eigenvalues suggested a 6-factor model, while the scree plot suggested a 7-factor model. The parallel analysis suggested a 3-factor model (3 factors having eigenvalues greater than the random median eigenvalues). The study team compared the three models and determined the 6-factor and 3-factor models had multiple cross-loadings, and that neither had clear factor interpretations. We, therefore, chose the 7-factor model because it had only one item with cross-loadings and the factors made theoretical sense.

A factor loading ≥0.4 was used for a cutoff. Two items ("Receive instructions on when and how to transition care from oncologist back to PCP", and "Clinician explains things about cancer follow up care in a way that is easy to understand") had weaker factor loadings (0.38 and 0.37, separately), but because they were close to the cutoff and conceptually important, the study team chose to retain them in the model. One item ("Patient has regular access to exercise and physical activity services") had cross-loadings on two factors ("Patient engagement" and "Prevention and wellness services"), and the study team categorized the item based on the higher loading. Two items ("Clinician can provide referrals to non-cancer specialty and follow-up services" and "Clinician provides information and guidance on who to call when experiencing health problems") had weak factor loadings (<0.35) and were therefore dropped from the model. In total, 36 items were included in the CFA analyses.

CFA was conducted to validate the model and each item was expected to load onto a single factor. Initially the CFA model did not meet the satisfactory fit of the data (X²=1637.17, df=573, p<0.001, RMSEA=0.054, CFI: 0.88, TLI:0.87, SRMR: 0.06). Based on the modification indices, we revised the CFA model and included 4 residual covariances between items (see Table 3). Three covariances can be explained by either similar wording (e.g. "Clinician discusses screening needs and recommendations for follow up" and "Clinician discusses late/long-term effects of cancer and treatment"); "Clinician provides patient with written treatment summary" and "Clinician provides patient with written survivorship care plan with recommendations for follow up care"; "Patient has regular access to exercise and physical activity services" and "Patient has regular access to nutrition and dietary services") and the fourth can be explained due to correlated content (e.g. “Patient has enough time to ask questions/voice concerns during visits” and “Clinician listens carefully to concerns related to patient health that may be related to cancer after treatment”). The final CFA model shows satisfactory model fit (X²=1356.52, df=569, p<0.001, RMSEA=0.047, CFI: 0.91, TLI: 0.90, SRMR: 0.06). Except for one item with a factor loading of 0.47 and another item with a factor loading of 0.56, all other factor loadings were greater than 0.6. The Cronbach's alpha ranges within 0.84-0.94. The coefficient omega ranges within 0.81-0.94, indicating high reliability for each factor. All 7 factors are highly correlated with the correlation coefficient ranging within 0.50-0.90 (ps<0.001). When the same CFA model was applied to the total sample, the model fit was greatly improved (X²=1712.461, df=569, p<0.001, RMSEA=0.040, CFI: 0.93, TLI: 0.92, SRMR: 0.05).
In the final CFA, the seven factors are: (1) information and support in survivorship (7 items); (2) having a medical home (10 items); (3) patient engagement in care (3 items); (4) survivorship care coordination (5 items); (5) insurance navigation (3 items); (6) care transitions from oncologist to primary care (3 items); and (7) prevention and general wellness.
Table 3  Final confirmatory factor analysis model

| Factors and Items | Factor-based score: Mean (SD): 3.38 (1.13), Cronbach’s α = 0.93, McDonald’s omega = 0.93, AVE=0.66 |
|-------------------|--------------------------------------------------------------------------------------------------|
| **Factor 1. Information and support in survivorship** | Factor-based score: Mean (SD): 3.53 (0.96), Cronbach’s α = 0.94, McDonald’s omega = 0.94, AVE=0.62 |
| Clinician discusses screening needs and recommendations for follow up care<sup>a</sup> | Standardized factor loading: 0.81 (0.02) | Standardized residual variance (1-R²): 0.338 | Explained variance (R²): 0.662 |
| Clinician discusses late/long-term side effects of cancer and treatment<sup>a</sup> | Standardized factor loading: 0.83 (0.03) | Standardized residual variance (1-R²): 0.318 | Explained variance (R²): 0.682 |
| Clinician helps patient follow through on recommendations for follow-up | Standardized factor loading: 0.81 (0.03) | Standardized residual variance (1-R²): 0.340 | Explained variance (R²): 0.660 |
| Clinician provides patient with written treatment summary<sup>b</sup> | Standardized factor loading: 0.76 (0.03) | Standardized residual variance (1-R²): 0.422 | Explained variance (R²): 0.578 |
| Clinician provides patient with written survivorship care plan with recommendations for FU care<sup>b</sup> | Standardized factor loading: 0.81 (0.02) | Standardized residual variance (1-R²): 0.340 | Explained variance (R²): 0.660 |
| Clinician and patient decide together when and how to transition from oncologist to PCP | Standardized factor loading: 0.82 (0.03) | Standardized residual variance (1-R²): 0.327 | Explained variance (R²): 0.673 |
| Clinician explains things about cancer follow up care in a way easy to understand | Standardized factor loading: 0.84 (0.02) | Standardized residual variance (1-R²): 0.296 | Explained variance (R²): 0.704 |
| **Factor 2. Medical home** | Factor-based score: Mean (SD): 4.14 (0.82), Cronbach’s α = 0.86, McDonald’s omega = 0.86, AVE=0.67 |
| Clinician explains reason for medical tests related to follow-up care | Standardized factor loading: 0.83 (0.02) | Standardized residual variance (1-R²): 0.304 | Explained variance (R²): 0.626 |
| Clinician addresses patient emotional concerns when discussing follow-up care | Standardized factor loading: 0.72 (0.03) | Standardized residual variance (1-R²): 0.481 | Explained variance (R²): 0.645 |
| Patient has enough time to ask questions/voice concerns during visits<sup>c</sup> | Standardized factor loading: 0.82 (0.02) | Standardized residual variance (1-R²): 0.327 | Explained variance (R²): 0.673 |
| Clinician listens carefully to concerns related to patient health that may be related to cancer after treatment<sup>c</sup> | Standardized factor loading: 0.84 (0.02) | Standardized residual variance (1-R²): 0.296 | Explained variance (R²): 0.704 |
| Clinician shows respect for what patient has to say about follow up care | Standardized factor loading: 0.83 (0.02) | Standardized residual variance (1-R²): 0.304 | Explained variance (R²): 0.626 |
| Clinician helps figure out reasons for new health care problems and whether they are related to cancer | Standardized factor loading: 0.80 (0.04) | Standardized residual variance (1-R²): 0.355 | Explained variance (R²): 0.645 |
| Patient has regular clinician/place to get health-care needs met including follow up care | Standardized factor loading: 0.84 (0.02) | Standardized residual variance (1-R²): 0.297 | Explained variance (R²): 0.703 |
| Patient has a point of contact to answer questions/concerns about follow-up care | Standardized factor loading: 0.84 (0.02) | Standardized residual variance (1-R²): 0.291 | Explained variance (R²): 0.709 |
| All clinicians can access medical records online or through EHR | Standardized factor loading: 0.67 (0.04) | Standardized residual variance (1-R²): 0.547 | Explained variance (R²): 0.453 |
| Patient has team of clinicians who all work together to address follow-up health care | Standardized factor loading: 0.68 (0.04) | Standardized residual variance (1-R²): 0.543 | Explained variance (R²): 0.457 |
| **Factor 3. Patient engagement** | Factor-based score: Mean (SD): 4.17 (0.86), Cronbach’s α = 0.90, McDonald’s omega = 0.91, AVE=0.66 |
| Patient is included in decision-making about your cancer-related follow-up care | Standardized factor loading: 0.72 (0.04) | Standardized residual variance (1-R²): 0.479 | Explained variance (R²): 0.521 |
| Patient is informed about what to do every day to take care of health and healthcare needs | Standardized factor loading: 0.88 (0.02) | Standardized residual variance (1-R²): 0.221 | Explained variance (R²): 0.779 |
| Patient feels in control of health and can manage health care needs | Standardized factor loading: 0.84 (0.03) | Standardized residual variance (1-R²): 0.303 | Explained variance (R²): 0.697 |
| **Factor 4. Care coordination** | Factor-based score Mean (SD): 4.17 (0.86) Cronbach’s α = 0.90, McDonald’s omega = 0.91 AVE=0.66 |
| All clinicians involved in care know patient’s medication | Standardized factor loading: 0.83 (0.02) | Standardized residual variance (1-R²): 0.314 | Explained variance (R²): 0.686 |
| All clinicians have medical files on cancer care | Standardized factor loading: 0.89 (0.02) | Standardized residual variance (1-R²): 0.205 | Explained variance (R²): 0.795 |
services (5 items). It is visually complex to present the 7 factors in a figure, so the factor structure is presented in Table 3 with standardized factor loadings and standard errors for each loading in the 2nd column. The standardized residual errors are presented in the 3rd column for each item. The R2 in column 4 indicates the standardized variance explained by the factors. Four pairs of items are bold to indicate residual correlations between the items ranging between 0.375 and 0.615. All the correlations between the latent factors are significant (ps<0.001), ranging within 0.498-0.828 (see Table 4).

Convergent validity

The convergent validity is measured by two methods: (1) reliability for each factor including Cronbach's alpha and McDonald's Omega, separately, and (2) the Average Variance Extracted (AVE) for each factor. The Cronbach's alpha and McDonald's Omega are greater than 0.7 for each of the latent factors. The AVE is calculated by getting the R2 value for each indicator in the CFA, adding them together and dividing by the total number of indicators [51]. The AVE for six factors are greater than 0.5 and AVE for one factor is close to 0.5, indicating convergent validity for the factors.

Table 3 (continued)

| Factors and items | Standardized factor loading | Standardized residual variance (1-R²) | Explained variance (R²) |
|-------------------|-----------------------------|--------------------------------------|------------------------|
| All clinicians share information with each other about follow-up care | 0.85 (0.03) | 284 | .716 |
| Clinicians can give patient the name of a doctor to make an appointment with if they need more follow-up care | 0.88 (0.02) | 221 | .779 |
| Patient receives complete physical exam with medical history | 0.56 (0.05) | 685 | .315 |
| Patient has help understanding insurance coverage options for medical services | 0.86 (0.02) | 266 | .734 |
| Patient has help understanding insurance coverage options for Rx and OTC drugs | 0.92 (0.02) | 161 | .839 |
| Patient has help with insurance problems, e.g. rejected claims | 0.79 (0.04) | 373 | .627 |
| Factor 5. Help navigating insurance | Factor-based score Mean (SD): 3.59 (1.11) Cronbach's α=0.89, McDonald's omega =0.89 AVE=0.73 |  |  |
| Patient has help understanding insurance coverage options for medical services | 0.86 (0.02) | 266 | .734 |
| Patient has help understanding insurance coverage options for Rx and OTC drugs | 0.92 (0.02) | 161 | .839 |
| Patient has help with insurance problems, e.g. rejected claims | 0.79 (0.04) | 373 | .627 |
| Factor 6. Care transitions | Factor-based score Mean (SD): 3.49 (1.12) Cronbach's α=0.86, McDonald's omega =0.88 AVE=0.71 |  |  |
| Receive instructions on when and how to transition care from oncologist back to PCP | 0.82 (0.02) | 324 | .676 |
| Patient remains under care of cancer doctor until ready to move care back to primary care doctor | 0.87 (0.03) | 237 | .763 |
| Cancer doctor stays informed of patient health after patient transfers care to primary care doctor | 0.83 (0.03) | 311 | .689 |
| Factor 7. Prevention and wellness services | Factor-based score Mean (SD): 3.06 (1.00) Cronbach's α=0.84, McDonald's omega =0.81 AVE=0.45 |  |  |
| Patient has regular access to exercise and physical activity services | 0.47 (0.05) | 781 | .219 |
| Patient has regular access to nutrition and dietary services | 0.63 (0.05) | 606 | .394 |
| Patient has regular access to risk reduction programs (e.g. weight loss, smoking cessation) | 0.72 (0.04) | 482 | .518 |
| Clinicians can provide referrals to patient for mental health effects related to cancer treatment | 0.76 (0.03) | 423 | .577 |
| Patient has support to manage roles and relationships with partner, family, and others | 0.75 (0.03) | 436 | .564 |

Note: 1. All standardized factor loadings are significantly different from zero (ps<0.001). 2. There are four pairs of residual error correlations with the corresponding items in bold: the correlation coefficient (r) between the residual errors of two items marked with * is 0.375 (p<0.001), r for the two items marked with ** is 0.491 (p<0.001), r for the two items marked with *** is 0.389 (p<0.001) and r for the items marked with **** is 0.615 (p<0.001). All the factors are positively correlated with the correlation coefficient ranging within 0.498-0.828 (all ps<0.001). The model fitness criteria: Chi-square: 1356.52(569), p<0.001, RMSEA: 0.047, CFI: 0.911, TLI: 0.902, SRMR:0.060. Factor-based score was created based on the mean of the scores of the items within each factor, accounting for sampling weight.
Factor-based scores
The factor-based scores for each factor were created based on the average of the scores of the items within each factor in the CFA model with the mean (SD) accounting for sampling weight shown in Table 3. The average score was estimated instead of the summary score as it has the advantage of being on the same scale for each factor and does not vary by the number of items. Only factors 1 and 2 show higher correlation (.82), likely due to the importance of communication in both factors (i.e., Information and support in survivorship and Medical Home).

Discussion
More can be done to ensure a comprehensive patient-centered approach to care that delivers the services and practices that help cancer survivors achieve better clinical outcomes and quality of life. In this study, we developed and validated a patient-centered survivorship care index that can be used to guide the development of survivorship programs and measure the patient-centeredness of care. The PC-SCI comprises seven multi-item factors that reflect cancer survivors’ priorities for survivorship care: Information and support in survivorship, medical home, patient engagement, care coordination, help navigating insurance, care transitions, and prevention and wellness services. These factors represent patient-centered resources and services that have been reported by patients to be priorities for survivorship care. Furthermore, the seven factors validated in the PC-SCI are well established in the literature as concepts critical to the provision of high-quality, patient-centered care and survivors’ long-term outcomes.

The PC-SCI highlights survivors’ desire for information and support to help with the long-term management of their post-treatment care. Studies show the importance of having well-informed patients who understand the trajectory of their health and wellness as a survivor and what to expect in the survivorship phase of their cancer care. When cancer treatment is completed, patients want a better understanding of “what happens next” [24, 25]. Uncertainty and lack of guidance may exacerbate patient challenges post-treatment [24, 25]. When care addresses information needs such as screening recommendations, care plans and treatment summaries, patients have clearer expectations, and they feel more prepared and grounded for the next stage in their health care [23, 24]. Provider support and help with follow-up also increase patients’ skill and confidence in making decisions and managing their care [26, 52].

The PC-SCI also highlights the patient-centered benefits of a medical home model for survivors, given its emphasis on the patient-provider relationship and patient-centered principles, such as communication and partnership between survivors and their clinicians, as well as the infrastructure support that enables continuity and coordination of care [28]. When providers utilize effective communication and shared decision-making and demonstrate respect, trust, and shared responsibilities with their patients, patients are more self-efficacious and have better physical and psychological health [20, 23]. Furthermore, strong communication and shared decision-making improve patients’ recovery, lessen symptoms, improve emotional health and support better overall quality of life [18, 53–55]. A medical home model for survivorship also typically takes a team-based approach with resources that facilitate access to continuous, follow-up care that can improve survivors’ overall health and well-being [56, 57].

Patient engagement is another key component of the PC-SCI. Patients who actively engage in decisions about their own care have been found to demonstrate higher self-efficacy, resulting in fewer barriers to care and improved clinical outcomes [21, 22, 26, 58]. Patient activation has also been shown to improve the uptake of preventive services and reduce risky behaviors [52]. The PC-SCI highlights survivors’ desire for better care coordination and transitions in survivorship care [25, 59]. Practices such as referral coordination, care management, and

|   | f1   | f2   | f3   | f4   | f5   | f6   | f7   |
|---|------|------|------|------|------|------|------|
| f1 | 1.00 |      |      |      |      |      |      |
| f2 | 0.82 | 1.00 |      |      |      |      |      |
| f3 | 0.60 | 0.68 | 1.00 |      |      |      |      |
| f4 | 0.58 | 0.64 | 0.55 | 1.00 |      |      |      |
| f5 | 0.62 | 0.60 | 0.50 | 0.52 | 1.00 |      |      |
| f6 | 0.72 | 0.65 | 0.48 | 0.64 | 0.59 | 1.00 |      |
| f7 | 0.70 | 0.68 | 0.50 | 0.52 | 0.62 | 0.69 | 1.00 |

Note: f1-f7 indicate factor-based scores for factor 1 to factor 7 in Table 3.
transition visits improve the patient experience, as well as the quality of care [20, 26, 60, 61]. With these practices in place, patient care is less fragmented and inconsistent, and may lower costs, reduce inappropriate care and improve health outcomes [56, 62]. Finally, the PC-SCI highlights the importance of a patient-centered, holistic approach to survivorship care that offers prevention and wellness services. Studies show patients want and need services such as mental health care referrals, dietary and exercise resources, and risk-reduction programs [9, 20, 25, 63, 64]. A patient-centered approach also recommends offering practical needs support, such as help navigating insurance [9, 24].

Future research should examine the use of the PC-SCI in clinical practice. A recommended approach would be to survey patients with item stem “During today’s visit” or “Following your visit today” or “On an ongoing basis, do you,” depending on the PC-SCI item. Responses should provide a range with a minimum of No/Yes/Don’t know/Don’t need or a range from Never to Always with a “Don’t know” and “Don’t need” option. This approach has been piloted among six state cancer coalitions and two tribal clinics using the Advancing Patient Centered Survivorship Care Toolkit, available online, which includes clinical support tools, workshop activities, assessment and evaluation tools based on the PC-SCI. See Supplemental Material for a formatted questionnaire. In addition, future studies might also use other statistical methods, e.g. Item Response Theory [65, 66], which can provide important information, e.g. item difficulty, discriminative ability, and might address other factor-related issues raised in this study.

As with all research, the current study has limitations that may affect the results. The survey consisted of self-reported data and is, therefore, subject to participant bias where respondents over- or under-report their experiences with certain items. In addition, while we aimed for a diverse cancer survivor sample, in line with other studies, our survey sample was mostly white, insured, had a history of breast cancer, with a mean age of 64. Therefore, more work needs to be done to validate the PC-SCI among more diverse groups, including diverse racial and ethnic groups, sexual and gender minorities, and those with a history of cancers other than breast cancer. In addition, priorities for patients’ survivorship care may differ by cancer types, treatment types or treatment phases, future studies might assess the constructs of survivorship care in the subpopulations of cancer survivors. Another limitation is that no related measures were included in this study for comparison. Future studies might include other existing survivorship care measures and assess the criterion validity of the survivorship care index by linking the indices to other existing measures.

Sampling and non-response bias, as well as survey error, are also challenges with all survey research. To address these concerns, the survey contractor GfK computed survey weights to offset known selection bias, including cancer type, and used a panel demographic post-stratification weight as an additional adjustment based on demographic distribution from the most recent Current Population Survey (CPS). While our statistical methods control for confounding factors, unaccounted influence could impact the results.

The survey was conducted in 2014 and much has evolved in cancer survivorship care since that time. However, issues related to how best to provide patient-centered survivorship care continue to challenge the field as noted by recent studies published by Hobden et al. and Tirodkar et al. [67, 68] These studies suggest gaps in patient-centered survivorship care still exist and more work is needed to support transformation of survivorship care programs to a truly patient-centered experience. Thus, the research team feels the PC-SCI is a relevant and useful contribution to the field as a tool that can help programs identify dimensions of patient-centeredness that can be improved upon.

Limitations related to the factor analysis could also affect the PC-SCI. While the research team aimed to develop a complete and accurate set of patient-centered practices in the survey by basing the work on theoretical models, conducting extensive formative work with survivors and using validated survey items [24], it is possible we missed important attributes, which could reduce the value of the index in measuring important aspects of patient-centered care.

**Conclusion**

Patient-centered care is a principal component of high-quality care. In order for care to be most effective, it must address patients’ self-identified needs, respect their values, consider their preferences in decision-making and respond to their priorities for better health and wellness [69]. As the field of survivorship care matures and professional standards are developed in the U.S., it is important to offer guidance that ensures care is both clinically optimal and patient-centered [70]. The PC-SCI provides cancer center clinicians and researchers with a validated tool to guide, measure, and monitor efforts that align quality survivorship goals with patient priorities for care.

**Abbreviations**

CER: Comparative Effectiveness Research; CFA: Confirmatory Factor Analysis; CFI: Comparative Fit Index; EFA: Exploratory Factor Analysis; FIML: Full Information Maximum Likelihood; KMO: Kaiser-Meyer-Olkin index of sampling adequacy; RML: The Robust Maximum Likelihood; RMSEA: Root Mean Square
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12913-021-07356-6.

Additional file 1.

Acknowledgements

Special thanks to Ruta Brazinskaite for her help formatting this manuscript.

Authors’ contributions

Authors KHM, SC, and MLP conceptualized the study. YW conducted EPA and CFA analyses. KHM, YW, HA and MLP contributed to writing and revision. All authors approved the final manuscript for submission.

Funding

Research reported in this paper was funded through PCORI® Award numbers IH-12-11-5255 and EADI-12744. The results presented in this work are solely the responsibility of the authors and do not necessarily represent the views of PCORI®, its Board of Governors or Methodology Committee.

Declarations

Ethics approval and consent to participate

All procedures performed in the study involving human participants were in accordance with the ethical standards of George Washington University and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The George Washington University Institutional Review Board approved the study (#101308). Informed consent was obtained from all individual participants included in the study.

Consent for publication

N/A

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

None of the authors of this paper have any conflicts of interest.

Author details

1Milken Institute School of Public Health, George Washington University, 950 New Hampshire Ave, Washington, DC 20052, USA. 2Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC 20008, USA. 3Department of Oncology, Georgetown Medical School, Washington, DC 20007, USA. 4George Washington University Cancer Center, George Washington University, 2600 Virginia Ave, NW, #300, Washington, DC 20005, USA.

Received: 7 September 2021   Accepted: 25 November 2021

Published online: 18 December 2021

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.

2. Miller KD, Nagourney L, Manotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85. https://doi.org/10.3322/caac.21565.

3. Survivorship 3.2021. NCCN clinical practice guidelines in oncology. 2021. https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf. Accessed 3 Nov 2021.

4. Jacobs LA, Shulman LN. Follow-up care of cancer survivors: challenges and solutions. Lancet Oncol. 2017;18(1):e19–29. https://doi.org/10.1016/S1470-2045(16)30386-2.

5. Edgerton A, Morgan MA. Looking beyond recurrence: comorbidities in cancer survivors. Clin J Oncol Nurs. 2011;15(1):E3–12. https://doi.org/10.1188/11.CJONE.E3-E12.

6. Hewitt ME, Greenfield S, Stovall E, National Cancer Policy Board (U.S.), Committee on Cancer Survivorship: Improving Care and Quality of Life. From cancer patient to cancer survivor: lost in transition. Washington, D.C.: National Academies Press; 2006.

7. National Cancer Institute at the National Institutes of Health. NCI dictionary of cancer terms website. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/survivorship. Accessed 4 Jun 2018.

8. McCabe MS, Bhatia S, Oeffinger KC, Reaman GH, Tyne C, Wollins DS, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol. 2013;31(5):631–40. https://doi.org/10.1200/JCO.2012.46.6854.

9. Kline RM, Arora NK, Bradley CJ, Brauer ER, Graves DL, Lunsford NB, et al. Long-term survivorship care after cancer treatment - summary of a 2017 National Cancer Policy Forum Workshop. J Natl Cancer Inst. 2018;110(12):1300–10. https://doi.org/10.1093/jnci/djy176.

10. Nekhlyudov L, Plant V, Bulsara M, Berg M. Systematic review and meta-analysis of patient reported outcomes for nurse-led models of survivorship care for adult cancer patients. Cancer Treat Rev. 2019;73:62–72. https://doi.org/10.1016/j.ctrv.2018.12.007.

11. Spears JA, Craft M, White S. Outcomes of cancer survivorship care provided by advanced practice RNs compared to other models of care: a systematic review. Oncol Nurs Forum. 2017;44(1):E34–41. https://doi.org/10.1188/17.ONF.E34-E41.

12. Nekhlyudov L, O’Malley DM, Hudson SV. Integrating primary care providers in the care of cancer survivors: gaps in evidence and future opportunities. Lancet Oncol. 2017;18(1):e30–6. https://doi.org/10.1016/S1470-2045(16)30570-8.

13. Lisý K, Kent J, Dumbrell J, Kelly H, Piper A, Jefford M. Sharing cancer survivorship care between oncology and primary care providers: a qualitative study of health care professionals’ experiences. J Clin Med. 2020;9. https://doi.org/10.3390/jcm902991.

14. Romkey-Sinasac C, Saunders S, Galica J. Canadian resources, programs, and models of care to support cancer survivors’ transition beyond treatment: a scoping review. Curr Oncol. 2021;28(3):2134–45. https://doi.org/10.3390/corumcol2803198.

15. Pham Q, Hearn J, Gao B, Brown I, Hamilton RJ, Berlin A, et al. Virtual care models for cancer survivorship. NPI Digit Med. 2020;3(1):113. https://doi.org/10.1038/s41746-020-00321-3.

16. Nekhlyudov L, Mollica MA, Jacobsen PB, Mayer DK, Shulman LN, Geiger AM. Developing a quality of cancer survivorship care framework: implications for clinical care, research, and policy. J Natl Cancer Inst. 2019;111(11):1120–30. https://doi.org/10.1093/jnci/djy089.

17. Rathert C, Wyrwich MD, Boren SA. Patient-centered care and outcomes: a systematic review of the literature. Med Care Res Rev. 2013;70(4):351–79. https://doi.org/10.1177/1077558712465774.

18. Stewart M, Brown JB, Donner A, Stewart M, Brown JB, Donner A, et al. Patient-centered care: a path to better health outcomes from the patient-owned survivorship care plan intervention. BMJ. 2016;353:i2000. https://doi.org/10.1136/bmj.i2000.

19. Kuipers SJ, Cramm JM, Nieboer AP. The importance of patient-centeredness and solutions. Lancet Oncol. 2017;18(1):e19–29. https://doi.org/10.1016/S1470-2045(16)30386-2.

20. Kuipers SJ, Cramm JM, Nieboer AP. The importance of patient-centered care and co-creation of care for satisfaction with care and physical and social well-being of patients with multi-morbidity in the primary care setting. BMC Health Serv Res. 2019;19(1):13. https://doi.org/10.1186/s12913-018-3618-y.

21. Park M, Giap TT, Lee M, Jeong H, Jeong M, Go Y. Patient- and family-centered care interventions for improving the quality of health care: a review of systematic reviews. Int J Nurs Stud. 2018;87:69–83. https://doi.org/10.1016/j.ijnurstu.2018.07.006.

22. Miller KL. Patient-centered care: a path to better health outcomes through engagement and activation. NeuroRehabilitation. 2016;34(4):465–70. https://doi.org/10.3233/nes-161378.

23. Kwale EA, Huang CS, Meneses KM, Demark-Wahnefried W, Bae S, Azuero CB, et al. Patient-centered support in the survivorship care transition: outcomes from the patient-owned survivorship care plan intervention. Cancer. 2016;122(20):3232–42. https://doi.org/10.1002/cncr.30136.

24. Little P, Everitt H, Williamson I, Warner G, Moore M, Gould C, et al. Observational study of effect of patient centredness and positive approach on outcomes of general practice consultations. BMJ. 2001;323(7318):908–11. https://doi.org/10.1136/bmj.323.7318.908.
24. Mead KH, Raskin S, Willis A, Areim H, Murtaza S, Charney L, et al. Identifying patients’ priorities for quality survivorship: conceptualizing a patient-centered approach to survivorship care. J Cancer Surviv. 2020;14(6):939–58. https://doi.org/10.1007/s11764-020-00905-8.

25. Mayer DK, Nasso SF, Earp JA. Defining cancer survivors, their needs, and perspectives on survivorship care in the USA. Lancet Oncol. 2017;18(1):e11–e8. https://doi.org/10.1016/s1470-2045(16)30573-3.

26. Loonen JJ, Blijlevens NM, Prins J, Dona DJ, Den Hartog J, Senden T, et al. Cancer survivorship care: person centered care in a multidisciplinary shared care model. Int J Integr Care. 2018;18(1):4. https://doi.org/10.5334/ijic.3046.

27. Willems RA, Bolman CA, Mesters J, Kanema IM, Beaulen AA, Lechner L. Cancer survivors in the first year after treatment: the prevalence and correlates of unmet needs in different domains. Psychooncology. 2016;25(1):51–7. https://doi.org/10.1002/pon.3870.

28. Tsui J, Hudson SV, Rubinstein EB, Howard J, Hicks E, Kieber-Emmons A, et al. A mixed-methods analysis of the capacity of the Patient-Centered Medical Home to implement care coordination services for cancer survivors. Transl Behav Med. 2018;8(3):219–27. https://doi.org/10.1093/tbm/ibx059.

29. Tzelepis F, Sanson-Fisher RW, Hall AE, Carey ML, Paul CL, Clinton-McHarg T. Development and psychometric evaluation of the Quality of Patient-Centered Cancer Care measure with hematological cancer survivors. Cancer. 2015;121(14):2383–92. https://doi.org/10.1002/cncr.29384.

30. Lisy K, Ly L, Kellie J, Cloke M, Jefford M. How do we define and measure optimal care for cancer survivors? An online modified reactive Delphi study. Cancers. 2021;13(10):2299.

31. Mead KH, Raskin S, Arem H, Landry M, Seyoum S, Cleary S, et al. Cancer survivorship care: person centered care in a multidisciplinary shared care model. Int J Integr Care. 2018;18(1):4. https://doi.org/10.5334/ijic.3046.

32. Lorig K. Outcome measures for health education and other health care interventions. Thousand Oaks: Sage Publications; 1996.

33. Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development and psychometric evaluation of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004;39(4 Pt 1):1005–26. https://doi.org/10.1111/j.1475-6773.2004.00269.x.

34. Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development and psychometric evaluation of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004;39(4 Pt 1):1005–26. https://doi.org/10.1111/j.1475-6773.2004.00269.x.

35. Cancer Survivors Survey of Needs May Clinic Cancer Center. https://prc.qdg.org/qualitymeasures/measures/1533401819895. Accessed 3 Nov 2021.

36. Daniel DM, Wagner EH, Coleman K, Schaefer JK, Austin BT, Abrams MK, et al. The effect of standardization on a χ2 approximation in confirmatory factor analysis. Multivariate Behav Res. 1995;30(3):377–93. https://doi.org/10.1207/s15327906mbr0102_10.

37. Horn JL. A rationale and test for the number of factors in factor analysis. Psychometrika. 1965;30:179–85. https://doi.org/10.1002/bfs2294944.

38. Greene J, Hibbard JH. Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med. 2015;22(7):520–6. https://doi.org/10.1007/s11606-015-3213-8.

39. Reid RJ, Coleman K, Johnson EA, Fishman PA, Hsu C, Soman MP, et al. The Group Health medical home at year two: cost savings, higher patient satisfaction, and less burnout for providers. Health Aff. 2010;29(5):835–43. https://doi.org/10.1377/hlj.2010.0158.

40. An J, Lau A. Economic evaluation of patient-centered care among long-term cancer survivors. Am J Manag Care. 2018;24(9):e292–e9.

41. Tirodkar MA, Accivastti N, Roth LM, Stovall E, Nasso SF, Sprando J, et al. Lessons from early implementation of a patient-centered care model in oncology. J Oncol Pract. 2015;11(6):456–61. https://doi.org/10.1200/JOP.2015.06072.

42. Meraviglia M, Stuifbergen A, Parsons D, Morgan S. Health promotion for cancer survivors: adaptation and implementation of an intervention. Holist Nurs Pract. 2013;27(3):140–7. https://doi.org/10.1177/0013164416658325.

43. Smith TG, Strollo S, Hu X, Earle CC, Leach CR, Nekhlyudov L. Understanding long-term cancer survivors’ preferences for ongoing medical care. J Gen Intern Med. 2019;34(10):2091–7. https://doi.org/10.1007/s11606-019-05189-y.

44. Goldenberg BA, Carpenter-Keltt T, Gingrich JR, Nugent Z, Sijer JJ. Moving forward after cancer: successful implementation of a colorectal cancer patient-centered transitions program. J Cancer Surviv. 2020;14(1):4–8. https://doi.org/10.1007/s11764-019-00819-0.

45. McCannery J, Winckworth-Prejnkar K, Schatz AA, Nardi EA, Dwyer AJ, Lieu C, et al. Addressing survivorship in cancer care. J Natl Compr Canc Netw. 2018;16(7):801–6. https://doi.org/10.6004/jnccn.2018.7054.

46. Evans JM, Matheson G, Buchman S, MacKinnon M, Meertens E, Ross J, et al. Integrating cancer care beyond the hospital and across the cancer care pathway: a patient-centered approach. Healthc Q. 2015;17:Spec No:28–32. https://doi.org/10.12927/hcq.2014.24006.

47. Cadet T, Davis C, Elks J, Wilson P. A holistic model of care to support those living with and beyond cancer. Healthcare. 2016;4(4):88. https://doi.org/10.1177/2055207616658325.

48. Maizes V, Rakel D, Niemiec C. Integrative medicine and patient-centered care. Explo. 2009;5(5):277–89. https://doi.org/10.1180/06.2008.

49. Ye ZJ, Zhang Z, Tang Y, Liang J, Sun Z, Zhang XY, et al. Development and psychometric analysis of the 10-item resilience scale specific to cancer: a multidimensional item response theory analysis. Eur J Oncol Nurs. 2019;41:64–71. https://doi.org/10.1016/j.ejon.2019.06.005.
66. Ye ZJ, Liang MZ, Zhang HW, Li PF, Ouyang XR, Yu YL, et al. Psychometric properties of the Chinese version of resilience scale specific to cancer: an item response theory analysis. Qual Life Res. 2018;27(6):1635–45. https://doi.org/10.1007/s11136-018-1835-2.

67. Hobden B, Turon H, Waller A, Carey M, Proietto A, Sanson-Fisher R. Gaps in patient-centered follow-up cancer care: a cross sectional study. J Psychosoc Oncol. 2021;39(2):161–72. https://doi.org/10.1080/07347332.2020.1815925.

68. Tirodkar MA, Roth L, Fuld Nasso S, Friedberg MW, Scholle SH. Facilitators and barriers to implementing a patient-centered oncology care model. JCO Oncol Pract. 2020;16(12):e1441–e150. https://doi.org/10.1200/OP.20.00231.

69. Barry MJ, Edgman-Levitan S. Shared decision making—pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780–1. https://doi.org/10.1056/NEJMmp1109283.

70. Halpern MT, Argenbright KE. Evaluation of effectiveness of survivorship programmes: how to measure success? Lancet Oncol. 2017;18(1):e51–9. https://doi.org/10.1016/S1470-2045(16)30563-0.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.